Demetra Tsapepas

List of Publications by Year
in descending order

54	1,990	394421 19	254184 43
papers	citations	h-index	g-index

54	54	54	4279
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. American Journal of Transplantation, 2020, 20, 1800-1808.	4.7	683
2	Acute Liver Injury in COVIDâ€19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. Hepatology, 2020, 72, 807-817.	7.3	269
3	Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation, 2021, 105, e265-e266.	1.0	136
4	Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1174-1178.	4.5	81
5	Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1041-1049.	4.5	52
6	Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. American Journal of Transplantation, 2020, 20, 3198-3205.	4.7	48
7	Outcomes of COVIDâ€19 in solid organ transplant recipients: A matched cohort study. Transplant Infectious Disease, 2021, 23, e13637.	1.7	47
8	High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PLoS ONE, 2020, 15, e0244131.	2.5	46
9	Direct oral anticoagulant considerations in solid organ transplantation: A review. Clinical Transplantation, 2017, 31, e12873.	1.6	41
10	Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection. American Journal of Transplantation, 2021, 21, 2254-2261.	4.7	40
11	A Donor Utilization Index to Assess the Utilization and Discard of Deceased Donor Kidneys Perceived as High Risk. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1634-1641.	4.5	38
12	Postvaccine Antiâ€“SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients. Kidney International Reports, 2021, 6, 1699-1700.	0.8	37
13	Patients prioritize waitlist over posttransplant outcomes when evaluating kidney transplant centers. American Journal of Transplantation, 2018, 18, 2781-2790.	4.7	34
14	Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients. American Journal of Kidney Diseases, 2021, 78, 314-317.	1.9	34
15	Financial impact of delayed graft function in kidney transplantation. Clinical Transplantation, 2020, 34, e14022.	1.6	31
16	Preformed Donor-Specific Antibodies and Risk of Antibody-Mediated Rejection in Repeat Renal Transplantation. Transplantation, 2014, 97, 642-647.	1.0	25
17	A longitudinal assessment of adherence with immunosuppressive therapy following kidney transplantation from the Mycophenolic Acid Observational REnal Transplant (MORE) study. Annals of Transplantation, 2014, 19, 174-181.	0.9	25
18	Sublingual Tacrolimus: A Pharmacokinetic Evaluation Pilot Study. Pharmacotherapy, 2013, 33, 31-37.	2.6	22

#	Article	IF	Citations
19	Engaging hospital patients in the medication reconciliation process using tablet computers. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1460-1469.	4.4	22
20	Perspectives on COVID-19 vaccination among kidney and pancreas transplant recipients living in New York City. American Journal of Health-System Pharmacy, 2021, 78, 2040-2045.	1.0	21
21	Incidence of Hyponatremia with High-Dose Trimethoprim-Sulfamethoxazole Exposure. American Journal of Medicine, 2016, 129, 1322-1328.	1.5	20
22	Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center. Diagnostic Microbiology and Infectious Disease, 2015, 81, 299-304.	1.8	19
23	Telehealth in outpatient management of kidney transplant recipients during COVIDâ€19 pandemic in New York. Clinical Transplantation, 2020, 34, e14097.	1.6	17
24	SARSâ€CoVâ€2 infection increases tacrolimus concentrations in solidâ€organ transplant recipients. Clinical Transplantation, 2021, 35, e14193.	1.6	14
25	Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in KidneyÂTransplantation. Kidney International Reports, 2018, 3, 281-290.	0.8	13
26	Using technology to enhance medication regimen education after solid organ transplantation. American Journal of Health-System Pharmacy, 2018, 75, 1930-1937.	1.0	12
27	Telemedicine pharmacy services implementation in organ transplantation at a metropolitan academic medical center. Digital Health, 2018, 4, 205520761878932.	1.8	12
28	Regional Disparities in Transplantation With Deceased Donor Kidneys With Kidney Donor Profile Index Less Than 20% Among Candidates With Top 20% Estimated Post Transplant Survival. Progress in Transplantation, 2019, 29, 354-360.	0.7	12
29	Utilization of Hepatitis C Virus (HCV)â€Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?. Hepatology, 2020, 71, 4-7.	7.3	11
30	Impact of Small Variations in the Delivered Dose of Rabbit Antithymocyte Induction Therapy in Kidney Transplantation With Early Corticosteroid Withdrawal. Transplantation, 2012, 94, 325-330.	1.0	10
31	Outcomes for potential kidney transplant recipients offered public health service increased risk kidneys: A singleâ€center experience. Clinical Transplantation, 2018, 32, e13427.	1.6	10
32	Impact of warm ischemia time on outcomes for kidneys donated after cardiac death Postâ€KAS. Clinical Transplantation, 2020, 34, e14040.	1.6	9
33	Home Care Delivery and Remote Patient Monitoring of Kidney Transplant Recipients During COVID-19 Pandemic. Progress in Transplantation, 2021, 31, 381-384.	0.7	9
34	Analysis of dendritic cells and ischemia-reperfusion changes in postimplantation renal allograft biopsies may serve as predictors of subsequent rejection episodes. Kidney International, 2018, 93, 1227-1239.	5.2	8
35	Treatment of borderline infiltrates with minimal inflammation in kidney transplant recipients has no effect on allograft or patient outcomes. Clinical Transplantation, 2020, 34, e14019.	1.6	8
36	Acyclovir versus Valganciclovir for Preventing Cytomegalovirus Infection in Intermediate-Risk Liver Transplant Recipients. Progress in Transplantation, 2015, 25, 39-44.	0.7	7

#	Article	IF	Citations
37	Using known drug interactions to manage supratherapeutic calcineurin inhibitor concentrations. Clinical Transplantation, 2017, 31, e13098.	1.6	7
38	Dynamic Interplay of Pharmacy Learners During a Solid Organ Transplantation Learning Experience. Journal of Pharmacy Practice, 2018, 31, 347-352.	1.0	7
39	Evaluation of kidney allocation critical data validity in the OPTN registry using dialysis dates. American Journal of Transplantation, 2020, 20, 318-319.	4.7	7
40	Managing the atazanavirâ€“tacrolimus drug interaction in a renal transplant recipient. American Journal of Health-System Pharmacy, 2011, 68, 138-142.	1.0	6
41	Medication stewardship using computerized clinical decision support: A case study on intravenous immunoglobulins. Pharmacology Research and Perspectives, 2019, 7, e00508.	2.4	6
42	Pharmacistâ€™s Role in Improving Medication Adherence in Transplant Recipients With Comorbid Psychiatric Disorders. Journal of Pharmacy Practice, 2019, 32, 568-578.	1.0	6
43	Content Coverage Evaluation of the OMOP Vocabulary on the Transplant Domain Focusing on Concepts Relevant for Kidney Transplant Outcomes Analysis. Applied Clinical Informatics, 2020, 11, 650-658.	1.7	6
44	A Comparison of Histamine Receptor Antagonists Versus Proton Pump Inhibitor Gastrointestinal Ulcer Prophylaxis in Kidney Transplant Recipients. Progress in Transplantation, 2017, 27, 4-9.	0.7	5
45	Retrospective analysis of the impact of severe obesity on kidney transplant outcomes. Nephrology Dialysis Transplantation, 2023, 38, 472-480.	0.7	4
46	An update to managing renal transplant ischemia reperfusion injury: novel therapies in the pipeline. Clinical Transplantation, 2013, 27, 647-648.	1.6	3
47	Risk evaluation and mitigation strategy programs in solid organ transplantation: the promises of information technology. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, e358-e362.	4.4	3
48	Challenged comparison of tacrolimus assays. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82, 246-250.	1.2	3
49	COVIDâ€19 infection in former living kidney donors. Clinical Transplantation, 2021, 35, e14230.	1.6	2
50	AÂNovel Antimicrobial Stewardship Program-Guided Procalcitonin Initiative for Emergency Department Diagnosis of Bacterial Pneumonia in New York City. Open Forum Infectious Diseases, 2017, 4, S27-S28.	0.9	1
51	ManagingÂtheÂsignificantÂinteraction between XR tacrolimus and fluconazole in kidney transplant recipients. Clinical Transplantation, 2020, 34, e14001.	1.6	1
52	The Reply. American Journal of Medicine, 2017, 130, e231.	1.5	0
53	Safety and Efficacy of Telavancin at an Outpatient Parenteral Antibiotic Therapy (OPAT) Unit in New York City. Open Forum Infectious Diseases, 2017, 4, S337-S337.	0.9	0
54	AB0461â€…BELATACEPT IN SLE KIDNEY TRANSPLANT PATIENTS. , 2019, , .		0